A Phase IB, Open-Label, Safety Study of the Combination of Sunitinib and Radiation for the Treatment of Patients With Cancer
Latest Information Update: 10 Nov 2021
Price :
$35 *
At a glance
- Drugs Sunitinib (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 14 Jan 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov
- 06 Nov 2013 Planned end date changed from 1 Mar 2013 to 1 Mar 2014 as reported by ClinicalTrials.gov.
- 06 Jan 2012 Actual patient number is 39 as reported by ClinicalTrials.gov